<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134263</url>
  </required_header>
  <id_info>
    <org_study_id>CYD17</org_study_id>
    <secondary_id>U1111-1114-7646</secondary_id>
    <nct_id>NCT01134263</nct_id>
  </id_info>
  <brief_title>Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia</brief_title>
  <official_title>Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to demonstrate that different CYD dengue vaccine lots
      manufactured using the same method and in the same location but at different times produce an
      equivalent immunological response after 3 doses.

      Primary Objective

        -  To demonstrate that three different Phase III lots of CYD dengue vaccine induce an
           equivalent immune response in terms of post-Dose 3 geometric mean titers (GMTs) against
           the four parental serotypes.

      Secondary Objectives:

        -  To demonstrate that data from one Phase II lot and pooled data from Phase III lots of
           CYD dengue vaccine show an equivalent immune response in terms of post-Dose 3 GMTs
           against the four parental serotypes.

        -  To describe the safety of the CYD dengue vaccine in all participants after each dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants received 3 doses of their assigned vaccine or placebo and provided blood
      samples at defined timepoints for flavivirus status and immunogenicity assessment. Safety
      data were collected in all participants after each dose and throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>An observer-blind procedure was followed for the three injections with CYD dengue vaccine or placebo. Neither the observer, Investigator, Sponsor, nor the participant knew which product was administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine</measure>
    <time_frame>28 days post-injection 3</time_frame>
    <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) assay. The lot-to-lot consistency between 3 Phase III lots was based on the use of the two-sided 95% confidence interval (CI) of the differences of the means of the log10 transformed post-vaccination titers between pairs of lots.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine</measure>
    <time_frame>28 days post-Injection 3</time_frame>
    <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using PRNT assay. Equivalence of Phase III vaccine with Phase II vaccine was assessed by Bridging between Phase III and Phase II Lot of CYD Dengue Vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Injection Site Reactions After Any Vaccination</measure>
    <time_frame>7 days post any vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Pain: Grade 3: Significant; prevents daily activity. Erythema and Swelling: Grade 3: &gt; 10 cm. Participants with Injection Site Reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions After Any Vaccination</measure>
    <time_frame>14 days post any vaccination</time_frame>
    <description>Solicited systemic reactions: Asthenia, Fever, Headache, Malaise and Myalgia. Fever: Grade 3: &gt;=39.0°C (&gt;=102.1°F). Headache, malaise, myalgia and asthenia: Grade 3: significant; prevents daily activity. Participants with systemic reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>CYD Dengue Vaccine Phase III Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYD Dengue vaccine - Phase III Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYD Dengue vaccine - Phase III Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYD Dengue vaccine - Phase II Lot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, recombinant dengue serotypes 1, 2, 3, &amp; 4 virus</intervention_name>
    <description>0.5 ml, Subcutaneous (SC)</description>
    <arm_group_label>CYD Dengue Vaccine Phase III Lot 1</arm_group_label>
    <other_name>CYD Dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, recombinant dengue serotypes 1, 2, 3, &amp; 4 virus</intervention_name>
    <description>0.5 ml, SC</description>
    <arm_group_label>CYD Dengue vaccine - Phase III Lot 2</arm_group_label>
    <other_name>CYD Dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, recombinant dengue serotypes 1, 2, 3, &amp; 4 virus</intervention_name>
    <description>0.5 ml, SC</description>
    <arm_group_label>CYD Dengue vaccine - Phase III Lot 3</arm_group_label>
    <other_name>CYD Dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, recombinant dengue serotypes 1, 2, 3, &amp; 4 virus</intervention_name>
    <description>0.5 ml, Subcutaneous (SC)</description>
    <arm_group_label>CYD Dengue vaccine - Phase II Lot</arm_group_label>
    <other_name>CYD Dengue vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo: NaCl 0.9%</intervention_name>
    <description>0.5 ml, SC</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 60 years on the day of inclusion.

          -  Informed consent form was signed and dated.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a woman of childbearing potential, use of an effective method of contraception, or
             abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks
             after the last vaccination (i.e., for 14 months).

        Exclusion Criteria:

          -  Known pregnancy, or a positive urine pregnancy test.

          -  History of flavivirus infection or vaccination or prolonged habitation in a dengue
             endemic area.

          -  Currently breastfeeding a child.

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the first trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except
             for pandemic influenza vaccination.

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Self-reported seropositivity for human immunodeficiency virus (HIV).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine used in the trial or to a vaccine containing
             any of the same substances.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily.

          -  Current alcohol abuse or drug addiction that might interfere with the ability to
             comply with trial procedures.

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion.

          -  Identified as a site employee of the Investigator or study center, with direct
             involvement in the proposed study or other studies under the direction of that
             Investigator or study center, as well as family members (i.e., immediate, husband,
             wife and their children, adopted or natural) of the site employees or the
             Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carina Heights</city>
        <zip>QLD 4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Enoggera</city>
        <zip>QLD 4051</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>VIC 3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Subiaco</city>
        <zip>WA 6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <zip>NSW 2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, Nissen MD, Richmond PC. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine. 2015 Sep 22;33(39):5127-34. doi: 10.1016/j.vaccine.2015.08.008. Epub 2015 Aug 13.</citation>
    <PMID>26279339</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <results_first_submitted>May 21, 2019</results_first_submitted>
  <results_first_submitted_qc>May 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue Fever</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD Dengue Vaccine</keyword>
  <keyword>Lot Consistency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 05 October 2010 to 26 November 2010 at 8 study sites in Australia.</recruitment_details>
      <pre_assignment_details>A total of 715 participants who met all of the inclusion criteria and none of the exclusion criteria were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYD Dengue Vaccine Phase III Lot 1</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="P2">
          <title>CYD Dengue Vaccine Phase III Lot 2</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="P3">
          <title>CYD Dengue Vaccine Phase III Lot 3</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="P4">
          <title>CYD Dengue Vaccine Phase II Lot</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="168"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="154"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="164">1 participant randomized to the Phase III Lot 2 group, received Phase III Lot 3 vaccination.</participants>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="143"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="149"/>
                <participants group_id="P5" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other adverse event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled, but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on Full Analysis Set included all participants who received at least 1 injection of CYD Dengue Vaccine or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>CYD Dengue Vaccine Phase III Lot 1</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="B2">
          <title>CYD Dengue Vaccine Phase III Lot 2</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="B3">
          <title>CYD Dengue Vaccine Phase III Lot 3</title>
          <description>Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="B4">
          <title>CYD Dengue Vaccine Phase II Lot</title>
          <description>Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months, subcutaneously.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="167"/>
            <count group_id="B5" value="57"/>
            <count group_id="B6" value="712"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="13.3"/>
                    <measurement group_id="B2" value="39.4" spread="12.9"/>
                    <measurement group_id="B3" value="38.7" spread="14.1"/>
                    <measurement group_id="B4" value="38.4" spread="13.2"/>
                    <measurement group_id="B5" value="39.7" spread="13.5"/>
                    <measurement group_id="B6" value="39.0" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine</title>
        <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) assay. The lot-to-lot consistency between 3 Phase III lots was based on the use of the two-sided 95% confidence interval (CI) of the differences of the means of the log10 transformed post-vaccination titers between pairs of lots.</description>
        <time_frame>28 days post-injection 3</time_frame>
        <population>Analysis was performed on Per-protocol analysis set which included participants who received at least 1 dose of the study vaccine or placebo and had no protocol deviations. Data for this outcome measure was not planned to be collected and analyzed for Phase II Lot and placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Phase III Lot 1</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Phase III Lot 2</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>CYD Dengue Vaccine Phase III Lot 3</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month12 (vaccination 3) , subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine</title>
          <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) assay. The lot-to-lot consistency between 3 Phase III lots was based on the use of the two-sided 95% confidence interval (CI) of the differences of the means of the log10 transformed post-vaccination titers between pairs of lots.</description>
          <population>Analysis was performed on Per-protocol analysis set which included participants who received at least 1 dose of the study vaccine or placebo and had no protocol deviations. Data for this outcome measure was not planned to be collected and analyzed for Phase II Lot and placebo.</population>
          <units>Titer (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="16.9" upper_limit="25.1"/>
                    <measurement group_id="O2" value="18.1" lower_limit="14.8" upper_limit="22.2"/>
                    <measurement group_id="O3" value="17.1" lower_limit="13.9" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" lower_limit="50.6" upper_limit="85.7"/>
                    <measurement group_id="O2" value="44.1" lower_limit="33.3" upper_limit="58.3"/>
                    <measurement group_id="O3" value="58.1" lower_limit="43.2" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="60.1" upper_limit="91.7"/>
                    <measurement group_id="O2" value="65" lower_limit="53.2" upper_limit="79.3"/>
                    <measurement group_id="O3" value="71.6" lower_limit="58.2" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" lower_limit="101.4" upper_limit="171.3"/>
                    <measurement group_id="O2" value="94.6" lower_limit="75.3" upper_limit="118.7"/>
                    <measurement group_id="O3" value="108.5" lower_limit="84.2" upper_limit="139.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1: Phase III Lot 1 vs Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1: Phase III Lot 2 vs Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.102</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1: Phase III Lot 3 vs Lot 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.080</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.204</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2: Phase III Lot 1 vs Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.174</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.340</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2: Phase III Lot 2 vs Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.297</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2: Phase III Lot 3 vs Lot 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.225</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3: Phase III Lot 1 vs Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.068</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3: Phase III Lot 2 vs Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.167</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3: Phase III Lot 3 vs Lot 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.144</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4: Phase III Lot 1 vs Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.144</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4: Phase III Lot 2 vs Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.207</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4: Phase III Lot 3 vs Lot 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency for each pair of lots was demonstrated if, for each pair of lots and each serotype the lower limit of the 95% CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.242</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine</title>
        <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using PRNT assay. Equivalence of Phase III vaccine with Phase II vaccine was assessed by Bridging between Phase III and Phase II Lot of CYD Dengue Vaccine.</description>
        <time_frame>28 days post-Injection 3</time_frame>
        <population>Analysis was performed on Per Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Pooled Phase III Lot</title>
            <description>Participants received 3 doses of CYD dengue vaccine one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3) from any of the Phase III Lots 1, 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Phase II Lot</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Pooled Phase III Lots (1, 2 or 3 )and Phase II Lot of CYD Dengue Vaccine</title>
          <description>GMTs against each of the 4 serotypes (serotype 1, serotype 2, serotype 3 and serotype 4) of dengue virus strains were assessed using PRNT assay. Equivalence of Phase III vaccine with Phase II vaccine was assessed by Bridging between Phase III and Phase II Lot of CYD Dengue Vaccine.</description>
          <population>Analysis was performed on Per Protocol Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for placebo.</population>
          <units>Titer (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue Virus Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="16.5" upper_limit="20.9"/>
                    <measurement group_id="O2" value="15.1" lower_limit="12.4" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" lower_limit="47.2" upper_limit="65.1"/>
                    <measurement group_id="O2" value="25.7" lower_limit="20.6" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="62.4" upper_limit="79.1"/>
                    <measurement group_id="O2" value="83.6" lower_limit="71.1" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue Virus Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.9" lower_limit="96.1" upper_limit="127.9"/>
                    <measurement group_id="O2" value="115.4" lower_limit="92.8" upper_limit="143.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 1</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>0.334</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.202</ci_lower_limit>
            <ci_upper_limit>0.466</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.173</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dengue Virus Serotype 4</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence between the pooled Phase III and Phase II was demonstrated if, for each serotype the lower limit of the 95%CI was &gt; -0.301 and the upper limit was &lt; 0.301.</non_inferiority_desc>
            <param_type>Difference of Log10 GMT</param_type>
            <param_value>-0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.137</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Injection Site Reactions After Any Vaccination</title>
        <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Pain: Grade 3: Significant; prevents daily activity. Erythema and Swelling: Grade 3: &gt; 10 cm. Participants with Injection Site Reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
        <time_frame>7 days post any vaccination</time_frame>
        <population>Analysis was performed on Safety Analysis Set which included all participants who received the study dose, and participants were analyzed according to the treatment received. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Phase III Lot 1</title>
            <description>Participants received 3 doses of 0.5 ml CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Phase III Lot 2</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>CYD Dengue Vaccine Phase III Lot 3</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>CYD Dengue Vaccine Phase II Lot</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site Reactions After Any Vaccination</title>
          <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Pain: Grade 3: Significant; prevents daily activity. Erythema and Swelling: Grade 3: &gt; 10 cm. Participants with Injection Site Reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
          <population>Analysis was performed on Safety Analysis Set which included all participants who received the study dose, and participants were analyzed according to the treatment received. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination</title>
        <description>Solicited systemic reactions: Asthenia, Fever, Headache, Malaise and Myalgia. Fever: Grade 3: &gt;=39.0°C (&gt;=102.1°F). Headache, malaise, myalgia and asthenia: Grade 3: significant; prevents daily activity. Participants with systemic reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
        <time_frame>14 days post any vaccination</time_frame>
        <population>Analysis was performed on Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Phase III Lot 1</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>CYD Dengue Vaccine Phase III Lot 2</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>CYD Dengue Vaccine Phase III Lot 3</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O4">
            <title>CYD Dengue Vaccine Phase II Lot</title>
            <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0(vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination</title>
          <description>Solicited systemic reactions: Asthenia, Fever, Headache, Malaise and Myalgia. Fever: Grade 3: &gt;=39.0°C (&gt;=102.1°F). Headache, malaise, myalgia and asthenia: Grade 3: significant; prevents daily activity. Participants with systemic reactions of any Grade (1, 2 or 3) and grade 3 were reported.</description>
          <population>Analysis was performed on Safety Analysis Set. Here, ‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="167"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asthenia: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="104"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 28 days after each dose of CYD dengue vaccine or Placebo. Solicited Reaction (SR) data were collected within 7 and 14 days after each vaccination. Serious adverse event (SAE) data were collected throughout the study, up to 30 days post-vaccination 3 (up to Month 13).</time_frame>
      <desc>Analysis was performed on Safety Analysis Set.</desc>
      <group_list>
        <group group_id="E1">
          <title>CYD Dengue Vaccine Phase III Lot 1</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>CYD Dengue Vaccine Phase III Lot 2</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="E3">
          <title>CYD Dengue Vaccine Phase III Lot 3</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="E4">
          <title>CYD Dengue Vaccine Phase II Lot</title>
          <description>Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stress Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bartholin's Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Muscle Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hypergammaglobulinaemia Benign Monoclonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma In Situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="140" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="49" subjects_at_risk="163"/>
                <counts group_id="E2" events="72" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E3" events="74" subjects_affected="58" subjects_at_risk="164"/>
                <counts group_id="E4" events="90" subjects_affected="69" subjects_at_risk="167"/>
                <counts group_id="E5" events="26" subjects_affected="20" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E3" events="31" subjects_affected="25" subjects_at_risk="164"/>
                <counts group_id="E4" events="32" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="122" subjects_affected="73" subjects_at_risk="163"/>
                <counts group_id="E2" events="114" subjects_affected="74" subjects_at_risk="161"/>
                <counts group_id="E3" events="122" subjects_affected="73" subjects_at_risk="164"/>
                <counts group_id="E4" events="122" subjects_affected="78" subjects_at_risk="167"/>
                <counts group_id="E5" events="15" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="110" subjects_affected="72" subjects_at_risk="163"/>
                <counts group_id="E2" events="116" subjects_affected="75" subjects_at_risk="161"/>
                <counts group_id="E3" events="146" subjects_affected="97" subjects_at_risk="164"/>
                <counts group_id="E4" events="126" subjects_affected="90" subjects_at_risk="167"/>
                <counts group_id="E5" events="43" subjects_affected="26" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="100" subjects_affected="70" subjects_at_risk="163"/>
                <counts group_id="E2" events="105" subjects_affected="69" subjects_at_risk="161"/>
                <counts group_id="E3" events="111" subjects_affected="72" subjects_at_risk="164"/>
                <counts group_id="E4" events="124" subjects_affected="84" subjects_at_risk="167"/>
                <counts group_id="E5" events="30" subjects_affected="21" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="188" subjects_affected="103" subjects_at_risk="163"/>
                <counts group_id="E2" events="186" subjects_affected="97" subjects_at_risk="161"/>
                <counts group_id="E3" events="208" subjects_affected="108" subjects_at_risk="164"/>
                <counts group_id="E4" events="201" subjects_affected="104" subjects_at_risk="167"/>
                <counts group_id="E5" events="61" subjects_affected="28" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

